Clinical trials
Triple Negative Breast Cancer clinical trials
Below are recruiting triple negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 438 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07283692RecruitingPhase 2
New drug combo for triple-negative breast cancer before surgery
This trial tests a new drug, serplulimab, combined with standard chemotherapy (paclitaxel and carboplatin) given before surgery for triple-negative breast cancer. The goal is to see if this combination can shrink tumors more effectively.
ShanghaiAges 18–70 - NCT07311993RecruitingPhase 1
Study of CLR 125 for triple negative breast cancer
This trial tests an experimental drug called CLR 125 in people with triple negative breast cancer that has worsened after at least one prior treatment. It aims to see if the drug is safe and how it affects the cancer.
Jacksonville, FloridaAges 18 years+ - NCT07327021RecruitingPhase 2
MRI-Guided treatment reduction for stage 2-3 triple-negative breast cancer
This trial tests if using MRI scans can safely reduce the amount of chemotherapy and immunotherapy needed before surgery for triple-negative breast cancer. All patients will receive the standard KEYNOTE-522 regimen, but the treatment may be tailored based on MRI results.
Tel AvivAges 18 years+ - NCT07332975Recruiting
Blood test for tumor DNA in early triple-negative breast cancer
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07342283RecruitingPhase 2
QL1706 plus chemo before surgery for triple-negative breast cancer
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
Nantong, JiangsuAges 18 years+ - NCT07351487RecruitingPhase 2
Chemo plus immunotherapy and anti-angiogenic drug for TNBC before surgery
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
HefeiAges 18–75 - NCT07357298RecruitingPhase 3
Brain MRI surveillance for stage IV breast cancer
This trial tests whether regular brain MRI scans can help detect brain metastases early in patients with stage IV breast cancer who do not yet have any known brain metastases. The goal is to see if early detection improves outcomes.
Miami, FloridaAges 18 years+ - NCT07371208RecruitingPhase 2
Sac-TMT plus immunotherapy before surgery for triple-negative breast cancer
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07394387RecruitingPhase 2
HIFU with or without immunotherapy before chemo for triple-negative breast cancer
This trial tests whether adding focused ultrasound (HIFU) and an immunotherapy drug (PD-1 inhibitor) before standard chemotherapy can improve outcomes for women with stage II or III triple-negative breast cancer (TNBC). It aims to find a more effective way to shrink tumors before surgery.
Nanjing, JiangsuAges 18–70 - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Birmingham, AlabamaAges 18 years+ - NCT02732860Recruiting
Test your tumor’s drug response using a lab model
This trial grows a lab model from your own tumor tissue (or resected tissue) to predict which drugs might work best. It’s meant to match investigational treatments to your specific tumor biology.
Toronto, OntarioAges 18 years+ - NCT02732171Recruiting
Blood and bone marrow tests to track breast cancer return
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
Philadelphia, PennsylvaniaAges 18 years+ - NCT02302742Recruiting
Registry for triple-negative breast cancer and inherited mutation carriers
This registry studies people with triple-negative breast cancer or inherited “HBOC” gene mutations (like BRCA, PALB2, PTEN, TP53). It collects information to better understand risk, outcomes, and how these cancers behave—helping future research and care.
Hays, KansasAges Any age - NCT02977468RecruitingPhase 1
Pembrolizumab for early triple-negative breast cancer tumor changes
This Phase 1 study tests pembrolizumab (an immune medicine) to see how it affects the tumor and its surroundings in triple-negative breast cancer. It’s mainly looking at safety and early signs of benefit, especially in a limited, early-stage breast tumor.
Atlanta, GeorgiaAges 21–80 - NCT02926690RecruitingPhase 1
MELK inhibitor safety study for advanced breast cancer
This Phase 1 study tests how safe a drug called an MELK inhibitor is in people with advanced breast cancer that has spread or cannot be removed with surgery. If you qualify, the study is focused on side effects and includes a special group for triple-negative breast cancer.
Norwalk, ConnecticutAges 18 years+ - NCT02945579Recruiting
Testing skipping breast surgery or radiation for top responders
This trial studies whether some people with early-stage breast cancer who respond extremely well to hormone/chemo/targeted treatment can safely skip breast surgery and/or radiation. It aims to reduce side effects without increasing cancer risk in carefully selected patients.
Gilbert, ArizonaAges 30 years+ - NCT07401537RecruitingPhase 2
Comparing two schedules of immunotherapy for advanced triple-negative breast cancer
This trial tests whether giving immunotherapy less often (extended dose intervals) works as well as the standard schedule for people with advanced triple-negative breast cancer who have already completed 6 cycles of first-line treatment. It aims to see if a longer break between doses can be just as effective with fewer hospital visits.
Guangzhou, GuangdongAges 18–70 - NCT07457359RecruitingPhase 2
Toripalimab plus radiation for chemo-resistant triple-negative breast cancer
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
HangzhouAges 18–75 - NCT07486089RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for advanced breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
Shenzhen, GuangdongAges 18–75 - NCT07327489Recruiting
Live tumor biopsy study to predict immunotherapy response
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
Fort Smith, ArkansasAges 18 years+ - NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
Phoenix, ArizonaAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07510802RecruitingPhase 1/Phase 2
CAR-NK cells for advanced HER2+ or triple-negative breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
Shenzhen, GuangdongAges 18–75 - NCT07513311Recruiting
Nurse Support Program for Triple-Negative Breast Cancer
This study tests a nurse-led coping and support program for people who recently finished treatment for triple-negative breast cancer. The program is designed to help you manage stress and emotional distress after treatment.
Boston, MassachusettsAges 18 years+
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for triple negative breast cancer?
- Yes. Clin2 currently lists 438 recruiting triple negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a triple negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a triple negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Metastatic Triple-negative Breast Cancer
- Advanced Triple Negative Breast Cancer
- Breast Cancer Triple Negative
- Triple Negative Breast Cancer (TNBC), Early Setting
- HER2-negative Breast Cancer
- Triple Negative Breast Neoplasms
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.